Zoledronate, Smoking, and Obesity Are Strong Risk Factors for Osteonecrosis of the Jaw: A Case-Control Study

Journal of Oral and Maxillofacial Surgery

Volumn 66, Issue 4, 2008, Pages 625-631

  Wessel, John H ^a   Dodson, Thomas B ^b   Zavras, Athanasios I ^c  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c RTI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; BUSULFAN; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; MELPHALAN; METHOTREXATE; NAVELBINE; PACLITAXEL; PAMIDRONIC ACID; TAMOXIFEN; TRASTUZUMAB; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; BONE NECROSIS; BREAST CARCINOMA; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; JAW; JAW NECROSIS; KIDNEY CARCINOMA; LUNG CARCINOMA; MALE; OBESITY; PROSTATE CARCINOMA; RISK ASSESSMENT; RISK FACTOR; SMOKING;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; JAW DISEASES; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; NEOPLASMS; OBESITY; OSTEONECROSIS; RISK FACTORS; SMOKING;

EID: 40749111524     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2007.11.032     Document Type: Article

References (26)

1. Hillner B.E., Ingle J.N., Berenson J.R., et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 18 (2000) 1378
2. Rosen L.S. Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors. Semin Oncol 29 (2002) 28
3. Kumar A., Loughran T., Alsina M., et al. Management of multiple myeloma: A systematic review and critical appraisal of published studies. Lancet Oncol 4 (2003) 293-304
4. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356 (2007) 1809
5. Kyle R.A. The role of bisphosphonates in multiple myeloma. Ann Intern Med 132 (2000) 734
6. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115
7. Ruggiero S.L., Mehrotra B., Rosenberg T.J., et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527
8. Bagan J.V., Murillo J., Jimenez Y., et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: Series of 10 cases. J Oral Pathol Med 34 (2005) 120
9. Migliorati C.A., Schubert M.M., Peterson D.E., et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy. Cancer 104 (2005) 83
10. Zavras A.I., and Zhu S. Bisphosphonate treatment and risk of surgery of the jaw. Is it osteonecrosis?. J Oral Maxillofac Surg 64 (2006) 917
11. Zervas K., Verrou E., Teleioudis Z., et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients. Br J Haematol 134 (2006) 620
12. Badros A., Weikel D., Salama A., et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 24 (2005) 945
13. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 23 (2005) 858
14. Dimitrakipoulos I., Magopoulos C., and Karakasis D. Bisphosphonate-induced avascular osteonecrosis of the jaws: A clinical report of 11 cases. Int J Oral Maxillofac Surg 35 (2006) 588
15. Santini D., Vincenzi B., Avvisati G., et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 104 (2002) 83
16. Ferretti G., Fabi A., Carlini P., et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 69 (2005) 35
17. Fournier P., Boissier S., Filleur S., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62 (2002) 6538
18. Borissova A.M., Tankova T., Kirilov G., et al. The effect of smoking on peripheral insulin sensitivity and plasma endothelin level. Diabetes Metab 30 (2004) 147
19. Whiteford L. Nicotine, CO and HCN: The detrimental effects of smoking on wound healing. Br J Community Nurs 8 (2003) S22
20. Silverstein P. Smoking and wound repair. Am J Med 93 (1992) 22S
21. Millar W.J., and Locker D. Smoking and oral health status. J Can Dent Assoc 73 (2007) 155
22. Albandar J.M., Steckfus C.F., Adesanya M.R., et al. Cigar, pipe, and cigarette smoking as a risk factor for periodontal disease and tooth loss. J Periodontol 71 (2000) 1874
23. Childs S. Osteonecrosis. Orthop Nurs 24 (2005) 295
24. Smith D. Is avascular necrosis of the femoral head the result of inhibition of angiogenesis?. Med Hypotheses 49 (1997) 497
25. Assouline-Dayan Y., Chang C., Greenspan A., et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 32 (2002) 94
26. Goldwaser B. Risk factor assessment for the development of osteoradionecrosis. J Oral Maxillofac Surg 64 (2006) 24